Blocking Peripheral H1 Receptors
Antihistamines occupy H1 receptors before histamine can trigger allergy symptoms.
- H1: Target receptor (Peripheral mast cell / endothelium)
- Inverse agonist: Mechanism (Stabilizes inactive receptor state)
- ~1 h: Onset (Peak plasma concentration)
- High: Selectivity (Minimal off-target receptors)
Receptor occupancy basics
Placeholder: drug binds H1 receptor, blocking histamine-driven itch, swelling, and redness.
Placeholder: higher occupancy correlates with stronger symptom control.
First-Generation vs Second-Generation Sedation
Older drugs like diphenhydramine cause drowsiness; newer ones largely avoid it.
- High: 1st-gen CNS entry (Lipophilic, crosses BBB freely)
- Low: 2nd-gen CNS entry (Polar, P-gp substrate)
- Common: Sedation (1st-gen) (Diphenhydramine, chlorpheniramine)
- Rare: Sedation (2nd-gen) (Cetirizine, loratadine)
Why sedation differs
Placeholder: brain H1 blockade causes drowsiness; second-gen drugs avoid this mostly.
Placeholder: reduced sedation improved daytime allergy treatment adherence.
Blood-Brain Barrier Penetration Difference
Tight junctions and efflux pumps keep most second-gen molecules outside the brain.
- Restrictive: Tight junctions (Block paracellular diffusion)
- Active efflux: P-glycoprotein (Pumps drug back to blood)
- Low (2nd-gen): Lipophilicity (Reduced passive diffusion)
- <30%: Brain occupancy (Second-generation drugs typical)
Barrier mechanisms
Placeholder: BBB structure and transporters limit CNS drug concentration.
Placeholder: P-glycoprotein is key to low brain penetration.
Cetirizine vs Loratadine Profile
Both are selective H1 blockers, but their CNS penetration differs slightly.
- ~28%: Cetirizine CNS (Slightly higher than loratadine)
- ~9%: Loratadine CNS (Very low, active metabolite)
- 8-24 h: Half-life (Once-daily dosing typical)
- Hepatic: Metabolism (Loratadine to desloratadine)
Comparing the two drugs
Placeholder: minor pharmacokinetic differences affect sedation and duration.
Placeholder: loratadine metabolite crosses BBB even less than parent drug.
Non-Sedating Symptom Relief Benefit
Patients get allergy relief for a full day without impaired alertness.
- 24 h: Duration (Once-daily coverage typical)
- Minimal: Cognitive impact (Compared to 1st-gen drugs)
- Improved: Driving safety (Less psychomotor impairment)
- Higher: Patient adherence (Fewer side effects reported)
Everyday benefit
Placeholder: non-sedating relief supports normal daily activity and work.
Placeholder: this is why second-gen drugs are now first-line therapy.